Size‐Tunable Nanoregulator‐Based Radiofrequency Ablation Suppresses MDSCs and Their Compensatory Immune Evasion in Hepatocellular Carcinoma

• DOI: 10.1002/adhm.202302013
• Publication Date: 2023-09-04T17:43:45Z
• Authors: Yuhao Tang; Zhilin Shu; Meiyan Zhu; Shuping Li; Yunyan Ling; Yizhen Fu; Zili Hu; Jiongliang Wang; Zhenyun Yang; Junbin Liao; Li Xu; Meng Yu; Zhenwei Peng
• Keywords: Evasion (ethics)

Radiofrequency ablation (RFA) is a widely used therapy for hepatocellular carcinoma (HCC). However, in cases of insufficient RFA (iRFA), nonlethal temperatures the transition zone increase risk postoperative relapse. The pathological analysis HCC tissues shows that iRFA-induced upregulation myeloid-derived suppressor cells (MDSCs) residual tumors critical recurrence. Furthermore, this study demonstrates, first time, combining MDSCs suppression strategy during iRFA can unexpectedly lead to compensatory PD-L1 expression on MDSCs, attributed relapse due immune evasion. To address issue, novel size-tunable hybrid nano-microliposome designed co-deliver inhibitors (IPI549) and αPDL1 antibodies (LPIP) multipathway activation responses. LPIP triggered release regulators by mild heat iRFA, selectively inhibiting blocking surviving MDSCs. combined + effectively ablates primary tumor activating responses while suppressing evasion This approach avoids post-iRFA incomplete model appears be promising eradication HCC.